Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AML Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AML

The FLT3 inhibitor, taken during chemotherapy and continued as a single agent for up to 3 years, significantly improved survival compared with standard chemotherapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news